References
- Pidaparti M, Bostrom B. Comparison of allergic reactions to pegasparaginase given IV vs. IM. Pediatr Blood Cancer. 2012;59:436–439.
- August KJ, Miller WP, Dalton A, et al. Comparison of hypersensitivity reactions to PEG-asparaginase in children after IV and IM administration. J Pediatr Hematol Oncol. 2013;35:e283–e286.
- Peterson WC, Clark D, Senn SL, et al. Comparison of allergic reactions to IV and IM pegaspargase in children with ALL. Pediatr Hematol Oncol. 2014;31:311–317.
- Abbott LS, Zakova M, Shaikh F, et al. Allergic reactions associated with IV versus IM pegaspargase: a retrospective chart review. Pediatr Drugs. 2015;17:315–321.
- MacDonald T, Kulkarni K Bernstein M, et al. Significantly higher incidence of allergic reactions for IV peg-asparaginase as compared to IM peg-asparaginase in children with high risk ALL. Pediatr Blood Cancer. 2014;61:S171.
- Alrazzak M, Beaupin LK, Kinyoun P, et al. The incidence of hypersensitivity reactions to pegylated asparaginase in children with ALL: a city-wide experience. J Pediatr Hemat Oncol. J Pediatr Hematol Oncol. 2016; 38:e16–e20.
- Maloney KW, Angiolillo AL, Schore RJ, et al. Association of IV and IM pegaspargase administration with rate of adverse events in standard risk ALL COG trials. ASCO Abstract and Poster. J Clin Oncol. 2015;33: Abstract 10035.
- Salzer W, Burke MJ, Larsen EC, et al., Incidence of allergic reactions to pegaspargase (PEG) administered intramuscularly versus intravenously (IM vs. IV) in children and young adults with high risk B-lymphoblastic leukemia (HR B-ALL): results of children's oncology group (COG) studies AALL0232/AALL1131. Blood. 2015;126:1303.
- Garay RP, El-Gewely R, Armstrong JK, et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9:1319–1323.
- Heitink-Pollé KM1, Prinsen BH, de Koning TJ, et al. High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase. JIMD Rep. 2013;7:103–108.
- Nussbaum V, Lubcke N, Findlay R. Hyperammonemia secondary to asparaginase: a case series. J Oncol Pharm Pract. 2016; 22:161–164.
- Szebeni J. Complement activation-ralated pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicol. 2005; 216:106–121.
- Corominas M, Gastaminza G, Lobera T. Hypersensitivity reactions to biological drugs. J Investig Allergol Clin Immunol. 2014; 24:212–225.